Ratings by Wedbush (Martin Fan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/17/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
16.06 (14.58) |
-9.22% | Details | |
| 4/27/2026 | Oruka Therapeutics | ORKA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Outperform (N/A) |
19.00 (41.17) |
116.68% | Details | |
| 4/20/2026 | Nektar Therapeutics | NKTR | Maintain | Neutral (N/A) |
|
Details | ||
| 4/14/2026 | Sana Biotechnology | SANA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
74.34 (71.75) |
-3.48% | Details | |
| 2/9/2026 | Zura Bio Ltd. | ZURA | New Coverage | Outperform (N/A) |
6.01 (5.65) |
-5.99% | Details | |
| 11/25/2025 | ImageneBio | IMA | New Coverage | Underperform (N/A) |
6.91 (5.02) |
-27.35% | Details | |
| 11/25/2025 | Vor Biopharma, Inc. | VOR | New Coverage | Neutral (N/A) |
8.36 (22.64) |
170.81% | Details | |
| 10/27/2025 | Fate Therapeutics | FATE | Upgrade | Outperform (Neutral) |
1.65 (2.43) |
47.27% | Details | |
| 9/24/2025 | Sana Biotechnology | SANA | New Coverage | Outperform (N/A) |
3.26 (3.83) |
17.48% | Details | |
| 7/9/2025 | Cartesian Therapeutics | RNAC | New Coverage | Outperform (N/A) |
11.30 (9.30) |
-17.7% | Details | |
| 5/28/2025 | Aclaris Therapeutis | ACRS | New Coverage | Outperform (N/A) |
1.27 (6.02) |
374.02% | Details | |
| 3/20/2025 | Zenas Biopharma | ZBIO | New Coverage | Outperform (N/A) |
8.25 (31.98) |
287.64% | Details |
